Table 2.

Evolution of glucose tolerance status.

No.	Combination therapy				Pasireotide-LAR first evaluation				Pasireotide-LAR last evaluation
	FBG (g/L)	HbA1c (%)	Glucose tolerance	Treatment	FBG (g/L)	HbA1c (%)	Glucose tolerance	Treatment modifications	FBG (g/L)	HbA1c (%)	Treatment modification
1	0.99	5.6	NGT		1.15	5.9	PD			6.1
2	1.19	7.2	TD	Met + dpp4	1.08	8.4	TD	insulin 4/d	Stop Pasireotide-LAR
3	0.97	5.8	PD		1.08	6.5	D		Stop Pasireotide-LAR
4	0.99	5.3	NGT		0.94	5.4	NGT		0.94	5.4
5	0.97	6.7	D		1.20	6.2	PD		1.01	6.3
6	1.03	5.8	PD		1.40	6.6	TD	Dpp4	1.80	7.2
7	0.99	5.8	PD		1.21	6.5	TD	Metf + dpp4	1.66	6.2
8	1.15	5.6	PD		1.20	6.2	PD		1.24	6.1
9	1.78	6.9	TD	Insulin 3/d	0.82	7.4	TD	Dose increase		10.9	Stop Pasireotide-LAR
10	1.4	6.5	TD	Met	NA	7.6	TD	+ Dpp4 - sulf	2.30	8.6	Stop Pasireotide-LAR
11	0.94	5.6	NGT		1.13	5.9	PD			6.1
12	0.90	5.4	NGT		1.03	5.9	PD		0.99	5.8
13	1.01	5.5	PD		1.17	6.0	PD		Stop Pasireotide-LAR
14	1.42	5.4	TD	Insulin 4/d	1.55	7.1	TD	+ Met	2.34	8.4	Stop Pasireotide-LAR
15	1.06	6.3	PD		1.60	6.3	D		Stop Pasireotide-LAR

D, diabetes not treated with a specific medication; Dpp4, dpp4 inhibitor; DT, diabetes treated with medication; Met, metformin; NA, not available; NGT, normal glucose tolerance; PD, prediabetes.